Genetic susceptibility to ulcerative colitis in the Chinese Han ethnic population: Association with TNF polymorphisms

Chinese Medical Journal

Volumn 119, Issue 14, 2006, Pages 1198-1203

  Cao, Qian ^a   Zhu, Qin ^a   Wu, Min Liang ^b   Hu, Wei Ling ^a   Gao, Min ^a   Si, Jian Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Polymorphism; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

TUMOR NECROSIS FACTOR;

ARTICLE; CAUCASIAN; CHINA; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

EID: 33746370729     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200607020-00011     Document Type: Article

References (20)

1. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996;16:459-467.
2. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D. Complex NF-KappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 1998;273:21178-21186.
3. Udalova IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell B, et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000;20:9113-9119.
4. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999;22:145-150.
5. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-406.
6. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997;34:391-399.
7. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-1466.
8. Braegger CP, Nicholl S, Murch SH, Stephens S, MacDonald TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
9. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomized controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-524.
10. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, et al. Tumor necrosis factor antibody treatment in Crohn's disease. Lancet 1993;342:173-174.
11. Van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-135.
12. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998;51:605-612.
13. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999;117:1062-1068.
14. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33:773-778.
15. Bouma G, Oudkerk Pool M, Scharenberg JG, Kolkman JJ, von Blomberg BM, Scheper RJ, et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995;30:1095-1100.
16. Vermeir S, Noman M, van Assche G, Baert F, van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-39.
17. Rutgeerts P, Sandbom WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
18. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhode JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-1035.
19. Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively. Immunogenetics 2002;53:1020-1027.
20. Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in Eastern China. Chin Med J 2005;118:747-752.